251 related articles for article (PubMed ID: 30853960)
1. Thioredoxin Modulates Protein Arginine Deiminase 4 (PAD4)-Catalyzed Citrullination.
Nagar M; Tilvawala R; Thompson PR
Front Immunol; 2019; 10():244. PubMed ID: 30853960
[TBL] [Abstract][Full Text] [Related]
2. The roles of PAD2- and PAD4-mediated protein citrullination catalysis in cancers.
Wang Y; Chen R; Gan Y; Ying S
Int J Cancer; 2021 Jan; 148(2):267-276. PubMed ID: 33459350
[TBL] [Abstract][Full Text] [Related]
3. Protein Arginine Deiminases (PADs): Biochemistry and Chemical Biology of Protein Citrullination.
Mondal S; Thompson PR
Acc Chem Res; 2019 Mar; 52(3):818-832. PubMed ID: 30844238
[TBL] [Abstract][Full Text] [Related]
4. Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4.
Martín Monreal MT; Rebak AS; Massarenti L; Mondal S; Šenolt L; Ødum N; Nielsen ML; Thompson PR; Nielsen CH; Damgaard D
Front Immunol; 2021; 12():716250. PubMed ID: 34737738
[TBL] [Abstract][Full Text] [Related]
5. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F
Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561
[TBL] [Abstract][Full Text] [Related]
6. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.
Curran AM; Naik P; Giles JT; Darrah E
Nat Rev Rheumatol; 2020 Jun; 16(6):301-315. PubMed ID: 32341463
[TBL] [Abstract][Full Text] [Related]
7. Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.
Knuckley B; Causey CP; Jones JE; Bhatia M; Dreyton CJ; Osborne TC; Takahara H; Thompson PR
Biochemistry; 2010 Jun; 49(23):4852-63. PubMed ID: 20469888
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.
Zhou Y; Chen B; Mittereder N; Chaerkady R; Strain M; An LL; Rahman S; Ma W; Low CP; Chan D; Neal F; Bingham CO; Sampson K; Darrah E; Siegel RM; Hasni S; Andrade F; Vousden KA; Mustelin T; Sims GP
Front Immunol; 2017; 8():1200. PubMed ID: 28993780
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine.
Martinez-Prat L; Palterer B; Vitiello G; Parronchi P; Robinson WH; Mahler M
Expert Rev Clin Immunol; 2019 Oct; 15(10):1073-1087. PubMed ID: 31524005
[No Abstract] [Full Text] [Related]
10. Discovery of Novel Potential Reversible Peptidyl Arginine Deiminase Inhibitor.
Aliko A; Kamińska M; Falkowski K; Bielecka E; Benedyk-Machaczka M; Malicki S; Kozieł J; Wong A; Bryzek D; Kantyka T; Mydel P
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052493
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a direct link between PAD4-mediated citrullination and the oxidative burst in human neutrophils.
Zhou Y; An LL; Chaerkady R; Mittereder N; Clarke L; Cohen TS; Chen B; Hess S; Sims GP; Mustelin T
Sci Rep; 2018 Oct; 8(1):15228. PubMed ID: 30323221
[TBL] [Abstract][Full Text] [Related]
12. Perspective on Protein Arginine Deiminase Activity-Bicarbonate Is a pH-Independent Regulator of Citrullination.
Zhou Y; Mittereder N; Sims GP
Front Immunol; 2018; 9():34. PubMed ID: 29403504
[TBL] [Abstract][Full Text] [Related]
13. Murine Retinal Citrullination Declines With Age and is Mainly Dependent on Peptidyl Arginine Deiminase 4 (PAD4).
Hollingsworth TJ; Radic MZ; Beranova-Giorgianni S; Giorgianni F; Wang Y; Iannaccone A
Invest Ophthalmol Vis Sci; 2018 Aug; 59(10):3808-3815. PubMed ID: 30073354
[TBL] [Abstract][Full Text] [Related]
14. Autocitrullination of PAD4 does not alter its enzymatic activity: In vitro and in silico studies.
Liu X; Wichapong K; Lamers S; Reutelingsperger CPM; Nicolaes GAF
Int J Biochem Cell Biol; 2021 May; 134():105938. PubMed ID: 33529715
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
16. Citrullination-Resistant LL-37 Is a Potent Antimicrobial Agent in the Inflammatory Environment High in Arginine Deiminase Activity.
Bryzek D; Golda A; Budziaszek J; Kowalczyk D; Wong A; Bielecka E; Shakamuri P; Svoboda P; Pohl J; Potempa J; Koziel J
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266231
[TBL] [Abstract][Full Text] [Related]
17. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
18. Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis.
Peng T; Li B; Bi L; Zhang F
Biomed Pharmacother; 2024 May; 174():116551. PubMed ID: 38636399
[TBL] [Abstract][Full Text] [Related]
19. Peptidyl arginine deiminase-4 exacerbates ischemic AKI by finding NEMO.
Rabadi MM; Han SJ; Kim M; D'Agati V; Lee HT
Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1180-F1190. PubMed ID: 30943066
[TBL] [Abstract][Full Text] [Related]
20. PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis.
Koushik S; Joshi N; Nagaraju S; Mahmood S; Mudeenahally K; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Apr; 21(4):433-447. PubMed ID: 28281906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
